Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies

Intrahepatic cholangiocarcinoma (ICC) remains a deadly malignancy lacking systemic therapies for advanced disease. Recent advancements include selective FGFR1–3 inhibitors for the 15% of ICC patients harboring fusions, although survival is limited by poor response and resistance. Herein we report ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidsky, Michael E., Wang, Zechen, Lu, Min, Liu, Annie, Hsu, S. David, McCall, Shannon J., Sheng, Zhecheng, Granek, Joshua A., Owzar, Kouros, Anderson, Karen S., Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588766/
https://www.ncbi.nlm.nih.gov/pubmed/36274097
http://dx.doi.org/10.1038/s41698-022-00320-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588766/
https://www.ncbi.nlm.nih.gov/pubmed/36274097
http://dx.doi.org/10.1038/s41698-022-00320-5

Ejemplares similares